검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Dendritic Cell Tumor Peptide Vaccine (Dendritic Cell Tumor Peptide Vaccine) Universidad Nacional de Colombia·Diffuse Hemispheric Glioma, H3 G34… 54 trials |
|---|---|
Overview Program | Dendritic Cell Tumor Peptide Vaccine |
Overview Company | Universidad Nacional de Colombia |
Overview Modality | ANTIBODY |
Overview Target | Diffuse Hemispheric Glioma, H3 G34-Mutan |
Overview Indication | Diffuse Hemispheric Glioma, H3 G34-Mutant |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | STING agonist 2'3'-cGAMP as an effective adjuvant for HPV16 peptide vaccine enhances anti-tumor immunity in TC-1 mice models.. Adjuvants are critical for enhancing vaccine immunogenicity. The agonists in cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway have demonstrated robust immune activation in preclinical models. Peptide vaccines targeting T cell epitopes… |
Clinical PFS | 19 |
Clinical OS | 52 |
Clinical Result source | ClinicalTrials.gov NCT02151448 |
Clinical Data Tier / Score | A · 18 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Dendritic Cell Tumor Peptide Vaccine (Dendritic Cell Tumor Peptide Vaccine) Universidad Nacional de Colombia·Diffuse Hemispheric Glioma, H3 G34… 54 trials |
|---|---|
Overview Program | Dendritic Cell Tumor Peptide Vaccine |
Overview Company | Universidad Nacional de Colombia |
Overview Modality | ANTIBODY |
Overview Target | Diffuse Hemispheric Glioma, H3 G34-Mutan |
Overview Indication | Diffuse Hemispheric Glioma, H3 G34-Mutant |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
MoA Mechanism | targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | STING agonist 2'3'-cGAMP as an effective adjuvant for HPV16 peptide vaccine enhances anti-tumor immunity in TC-1 mice models.. Adjuvants are critical for enhancing vaccine immunogenicity. The agonists in cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway have demonstrated robust immune activation in preclinical models. Peptide vaccines targeting T cell epitopes… |
Clinical PFS | 19 |
Clinical OS | 52 |
Clinical Result source | ClinicalTrials.gov NCT02151448 |
Clinical Data Tier / Score | A · 18 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교